Tomasz Sablinski from Transparency Life Sciences showed at the DayOne Expert event - Next Generation Clinical Trials ways to virtualize clinical trials or parts of them.

1. Transparency Life Sciences
DayOne Basel
June 25, 2019

2. Unique, Highly Differentiated Clinical Trials Partner
The unique Transparency Virtual Trials platform could immediately be applied to
25% of clinical trials:
• Design: Transparency Protocol Crowdsourcing - proprietary tool for
stakeholders (sponsors, patients, physicians) to co-design clinical study
protocols
• Execution: as a technology enabled service, the Transparency Virtual Trials
platform offers the unique combination of high technology (wearable,
handheld devices) with study personnel - patient interactions via
telemedicine;
The TLS comprehensive clinical trial design and execution offering translates into
better designed, patient-centric protocols which facilitate patient recruitment and
retention.
• Biopharma sponsors benefit from higher quality and increased density of
data resulting in shorter and less expensive clinical trials.
Transparency Life Sciences is the only company exclusively designing and
conducting virtual (digital) and hybrid clinical trials.

3. Transparency Protocol Crowdsourcing™
Better protocols
Patients selected and “soft-screened” before enrollment
begins
Potential to consent patients in days vs standard of
months
Strong support from FDA
Multiple TLS trial designs approved by major U.S.
academic IRB’s
Protocols crowdsourced in CNS, GI, cancer,
autoimmune
Results of prostate cancer project published in JNCI
Transparency Crowdsourcing collects, curates input
from global community of patients, MDs, researchers

4. Fully Virtual Clinical Trials Platform is Ready
Protocol
crowdsourcing
Better design
Online recruitment
Faster
eConsent
can consent all
patients within days
Delivery/training
monitoring
equipment
Medication
administration,
adherence, & vitals
monitoring
eDiary/ePRO
surveys
Higher quality data
Telehealth for
exams & protocol
assessments
Better adherence
In-home visits
Higher patient
retention
Cloud-based data
aggregation,
warehousing &
visualization
Real time analysis
Patients participate digitally and in whole or in part from home
in the clinical trial process
Transparency Protocol Crowdsourcing™ + Transparency Virtual Trials™

5. Therapeutic Areas
phase II, IV target
autoimmune CNS
chronic cancers
dermatology GI diseases
rare diseases
straight-
forward
ease of
in-home
execution
difficult
acute indication chronic
MI, stroke,
acute cancer
examples of
great fits:
• CNS / Ph II
• RA or IBS / Ph IV
compound
characteristics:
• oral ↑
• topical ↑
• IM/S.C. ↓
• IV ↓
Opportunity to enhance patient-centricity
phase I, III
ophthalmology